Skip to content

A real-world study of aprepitant injection for the prevention of postoperative nausea and vomiting

A real-world study of aprepitant injection for the prevention of postoperative nausea and vomiting

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094420
Enrollment
Unknown
Registered
2024-12-23
Start date
2024-12-23
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and vomiting

Interventions

Experimental group:Aprepitant

Sponsors

Chongqing Changshou District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Age >=18 years old; 2) Expect to receive surgical treatment; 3) Apfel risk simplicity score >=2 points; 4) Meet the American Society of Anesthesiologists (ASA) grading standards Level I-III; 5) The function of vital organs meets all the following requirements: a) Liver function: i.st, ALT and ALP= 60 mL/min (CrCl calculated according to Cockcroft-Gault formula) or serum creatinine <=1.5×ULN; 6) Subjects voluntarily participate in the study and are able to comply with treatment, periodic evaluation, follow-up and other requirements related to the study, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women. 2) Patients with vomiting for any reason within 24 hours before surgery; 3) Received any antiemetic drugs (including but not limited to NK-1R antagonists, 5-HT3 receptor antagonists, corticosteroids (except for topical application), traditional Chinese medicine or proprietary Chinese medicine) or prophylactic antiemetic drugs within 1 week before enrollment. 4) The presence of any past or current medical conditions, treatments, or laboratory abnormalities that may confuse the study results, interfere with participants' full participation in the study, or that participation in the study may not be in the subjects' best interests.

Design outcomes

Primary

MeasureTime frame
24-hour complete response (CR) after surgery;

Secondary

MeasureTime frame
48-hour complete response (CR) after surgery;Proportion of patients without vomiting (with or without salvage therapy) in 24 and 48 hours after surgery;Proportion of patients received salvage therapy;time to treatment failure;safety;

Countries

China

Contacts

Public ContactQi Jun

Chongqing Changshou District People's Hospital

421539324@qq.com+86 130 3639 9093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026